Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cyproterone acetate 2mg;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg   ethinylestradiol 0.035mg   excipient: croscarmellose sodium opaglos 6000 white lactose monohydrate magnesium stearate microcrystalline cellulose opadry buff oy-3690 opadry white y-1r-7000b povidone purified water quinoline yellow sucrose - estelle-35 and estelle-35 ed are indicated for the treatment of androgen dependent diseases in women, such as acne (where oral antibiotics or local treatment alone has not been successful), especially pronounced forms and those which are accompanied by seborrhoea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgenic alopecia, mild forms of hirsutism. estelle-35 and estelle-35 ed are also indicated for oral contraception in women requiring treatment for these androgen-dependent diseases; it is not recommended in women solely for contraception. estelle-35 and estelle-35 ed are also indicated for treating the symptoms of polycystic ovary syndrome.

Filipinai - anglų - FDA (Food And Drug Administration)

lloyd labs inc - cypoterone acetate , ethinylestradiol estradiol - tablet, film coated - 2mg+35mg

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

rex medical ltd - cyproterone acetate 2mg;  ;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg     ethinylestradiol 0.035mg   excipient: hypromellose lactose monohydrate magnesium stearate povidone propylene glycol purified talc   quinoline yellow starch titanium dioxide - androgen-dependent diseases in women are an indication for treatment with ginet-63. these diseases may include: acne (where local treatment or oral antibiotics alone have not been successful), especially pronounced forms of acne that may be accompanied by inflammation or formation of nodes (acne nodulocystica, acne papulopustulosa), seborrhea, mild forms of hirsutism and/or androgenic alopecia. oral contraception in women requiring treatment for these androgen-dependent diseases is an indication for treatment with ginet-63. however ginet-63 is not recommended in women solely for contraception.

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - cyproterone acetate; ethinylestradiol - oral tablet - 2mg ; 35microgram

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; gelatin; maize starch; macrogol 4000; magnesium stearate; hypromellose; lactose monohydrate - oral contraception

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: gelatin; hypromellose; iron oxide yellow; titanium dioxide; magnesium stearate; lactose monohydrate; maize starch; macrogol 4000 - oral contraception

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate -

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - cyproterone acetate; ethinylestradiol - oral tablet - 2mg ; 35microgram

Airija - anglų - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - cyproterone acetate, ethinylestradiol - coated tablets - 2mg/35 microgram - antiandrogens and estrogens

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - cyproterone acetate; ethinylestradiol - oral tablet - 2mg ; 35microgram